Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

O'Donnell KL. et al, (2024), International journal of molecular sciences, 25

Translational Science at the Undergraduate Level: Awakening Talents to Overcome the Valley of Death – Viewpoint Showing a Success Case (Preprint)

Ferreira Jr RS. et al, (2024)

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Costa Clemens SA. et al, (2024), The Lancet. Microbe

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

Flaxman A. et al, (2024), PLoS pathogens, 20

Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

Bissett C. et al, (2024), NPJ vaccines, 9

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease

Drury RE. et al, (2024), Nature Communications, 15

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.

Port JR. et al, (2023), Nature communications, 14

Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.

Waerlop G. et al, (2023), Journal of immunological methods, 523

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.

Mitsi E. et al, (2023), Nature communications, 14

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.

Neale I. et al, (2023), mBio

Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.

Maze EA. et al, (2023), Viruses, 15

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.

Ramasamy MN. et al, (2023), The Lancet. Microbe

The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.

Dzau V. et al, (2023), Lancet (London, England)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Costa Clemens SA. et al, (2023), Human vaccines & immunotherapeutics, 19

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H. et al, (2023), Nature communications, 14

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), The Journal of infection, 87, 18 - 26

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Barnes E. et al, (2023), Nature Medicine, 29, 1760 - 1774

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Kaplonek P. et al, (2023), Nature immunology

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), The Journal of infection, 86, 574 - 583

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?